perhaps they will reach an agreement sometime down the road, if the vaccine works. they are closed lip on the mixture of the delivery system, which is understandable, considering how many eyes are on them worldwide. remember abus felt they were owed "low single figure royalties" which could change with events. IMO.
Are you aware of any other clinically validated LNP delivery platforms other then ABUS/Genevant?
“This partnership with Genevant will allow us to access a highly potent, clinically validated LNP delivery platform,” said Prof. Ugur Sahin, Co-Founder and Chief Executive Officer of BioNTech. “Genevant’s liver-targeted platform complements our existing capabilities for dendritic cell-specific delivery of mRNA encoded antigens used in the development of our cancer vaccine pipeline.
News 
Market Data 
Discover 
AI
